Wall Street analyst estimates for Dianthus Therapeutics, Inc. (DNTH): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production,...
Consensus price target
$132.60 (+60 % vs price $82.70)
between $120.00 and $158.00 · 3 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $1.9M | $1.1M – $2.5M | -$3.79 | 11 |
| 2027E | $2.1M | $1.3M – $3.5M | -$4.60 | 11 |
| 2028E | $13.6M | $7.6M – $21.6M | -$5.64 | 13 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 10 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (−2 sell to +2 buy) | 1.09 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.94 | ||
| 2026-08-04 | $-0.90 | $-0.85 | -6.3% |
| 2026-05-05 | $-0.85 | $-1.17 | +27.4% |
| 2026-03-09 | $-1.43 | $-0.98 | -45.9% |
| 2025-11-05 | $-0.97 | $-0.86 | -12.8% |
| 2025-08-07 | $-0.88 | $-0.86 | -2.3% |
| 2025-05-12 | $-0.82 | $-0.86 | +4.7% |
| 2025-03-11 | $-0.81 | $-0.85 | +4.7% |
Valuation Ratios
| Price / Book | 3.95 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Cost of Revenue | $6,000 | $376,000 | $875,000 | $1.8M | $2.0M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$6,000 | -$376,000 | -$875,000 | -$1.8M | -$2.0M | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Research & Development | $5.8M | $27.9M | $41.3M | $57.4M | $48.6M | $12.6M | $29.4M | $32.8M | $83.1M | $145.6M |
| Selling, General & Admin | $3.5M | $7.5M | $17.7M | $23.8M | $28.1M | $2.0M | $6.7M | $18.2M | $25.0M | $34.3M |
| Operating Expenses | $9.3M | $35.4M | $59.1M | $81.1M | $76.7M | $14.6M | $36.1M | $51.0M | $108.1M | $180.0M |
| Operating Income | -$9.3M | -$35.7M | -$60.0M | -$83.0M | -$78.7M | -$13.1M | -$29.7M | -$48.2M | -$101.9M | -$177.9M |
| EBITDA | -$9.3M | -$35.1M | -$56.6M | -$74.9M | -$73.0M | -$11.1M | -$28.3M | -$43.2M | -$84.6M | -$161.9M |
| Interest Expense | $163,000 | 0 | 0 | 0 | $3.8M | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$9.4M | -$35.5M | -$57.5M | -$76.8M | -$74.9M | -$13.1M | -$28.5M | -$43.6M | -$85.0M | -$162.3M |
| Income Tax | 0 | $236,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$9.4M | -$35.5M | -$57.5M | -$76.8M | -$74.9M | -$13.1M | -$28.5M | -$43.6M | -$85.0M | -$162.3M |
| EPS | -$4.27 | -$16.05 | -$27.62 | -$33.18 | -$27.30 | -$3.82 | -$7.60 | -$8.45 | -$2.55 | -$4.20 |
| EPS (Diluted) | -$4.27 | -$16.05 | -$27.62 | -$33.18 | -$27.30 | -$3.82 | -$7.60 | -$8.45 | -$2.55 | -$4.20 |
| Shares Outstanding (Diluted) | 2.2 M | 2.2 M | 2.1 M | 2.3 M | 2.7 M | 3.4 M | 3.7 M | 5.2 M | 33.3 M | 37.8 M |
Price
| Price | $82.70 (closing price, November 3, 2026) |
| Market Cap | $4.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: IMVT · VERA · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DNTH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks